ARID4B and prostate cancer: By analyzing the Cancer Genome Atlas (TCGA) and other prostate cancer genomic datasets2,20,24,25,34, we identified that ARID4B is consistently retained in prostate carcinoma cohorts with deep deletion of PTEN, although deletion of ARID4B also occasionally occurs in prostate cancer (Fig. 3a).